First of its kind approach that allows New Chemical Entities to be developed under a 505(b)2 development path, validated by the USFDA and MHRA
Intellectual property protection through Composition of Matter patent, validated by issuance of patents by the US, EU, China, Japan and other PTOs.
Facilitates the repurposing, repositioning, reprofiling, and rescuing of generic and proprietary drugs.
Diverse applicability, addressing diseases from oncology to pain, mitochondrial function to cardiovascular, renal to neurodegeneration, metabolic disorders to ageing…….
For patients - unprecedented value For investors - Significant return with significantly lower risk For society - Healthcare savings and increased productivity
